Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Crispr Therapeutics AG (CRSP)

Analysts fell to the sidelines weighing in on Blueprint Medicines (BPMCResearch Report) and Crispr Therapeutics AG (CRSPResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Blueprint Medicines (BPMC)

SVB Securities analyst Andrew Berens maintained a Hold rating on Blueprint Medicines today and set a price target of $60.00. The company’s shares closed last Friday at $48.07, close to its 52-week low of $47.71.

According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -9.1% and a 40.5% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $86.25 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Crispr Therapeutics AG (CRSP)

In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Crispr Therapeutics AG, with a price target of $57.00. The company’s shares closed last Friday at $63.76.

According to TipRanks.com, Burnett ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.2% and a 18.9% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Atara Biotherapeutics, and Precision BioSciences.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $101.27.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed